|
JP4976412B2
(ja)
|
2005-12-01 |
2012-07-18 |
ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー |
エンドセリン、エンドセリンアゴニスト及びアドレノメジュリンアンタゴニストによる危篤患者の診断及び治療のための方法
|
|
ES2828739T3
(es)
|
2006-04-07 |
2021-05-27 |
Aerpio Pharmaceuticals Inc |
Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
|
|
TWI510246B
(zh)
|
2010-04-30 |
2015-12-01 |
Molecular Partners Ag |
抑制vegf-a受體交互作用的經修飾結合性蛋白質
|
|
AU2014243418B2
(en)
*
|
2010-04-30 |
2016-09-22 |
Molecular Partners Ag |
Modified binding proteins inhibiting the VEGF-A receptor interaction
|
|
EP3514169B1
(en)
|
2010-11-26 |
2024-03-06 |
Molecular Partners AG |
Designed repeat proteins binding to serum albumin
|
|
WO2012149439A2
(en)
|
2011-04-29 |
2012-11-01 |
Janssen Biotech, Inc. |
Il4/il13 binding repeat proteins and uses
|
|
WO2012172054A1
(en)
|
2011-06-16 |
2012-12-20 |
Scil Proteins Gmbh |
Modified multimeric ubiquitin proteins binding vegf-a
|
|
MX363351B
(es)
|
2011-10-13 |
2019-03-20 |
Aerpio Therapeutics Inc |
Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular.
|
|
PL3553084T3
(pl)
|
2011-11-16 |
2023-04-17 |
Adrenomed Ag |
Przeciwciało przeciwko adrenomedulinie (adm) lub fragment przeciwciała przeciwko adm lub szkielet przeciwko adm inny niż ig do profilaktyki lub zmniejszania zaburzenia czynności narządu lub niewydolności narządu u pacjenta cierpiącego na przewlekłą lub ostrą chorobę lub ostry stan
|
|
HRP20190122T1
(hr)
|
2011-11-16 |
2019-03-08 |
Adrenomed Ag |
Protutijelo protiv adrenomedulina (adm) ili fragment protutijela protiv adm ili okosnica ne-ig protiv adm, namijenjeni reguliranju ravnoteže tekućina kod pacijenta s kroničnom ili akutnom bolešću
|
|
BR112014011670B1
(pt)
|
2011-11-16 |
2021-05-25 |
Adrenomed Ag |
anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou um arcabouço de proteína não-igg anti-adm que se liga à adrenomedulina e formulação farmacêutica
|
|
HRP20191771T1
(hr)
|
2011-11-16 |
2019-12-27 |
Adrenomed Ag |
Anti-adrenomedulin (adm) antitijelo ili fragment anti-adm antitijela ili anti-adm non-ig skela za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta za stabiliziranje cirkulacije
|
|
US9140696B2
(en)
|
2011-11-16 |
2015-09-22 |
Adrenomed Ag |
Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-IG scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
|
|
ES2494190T3
(es)
|
2011-11-16 |
2014-09-15 |
Adrenomed Ag |
Anticuerpo anti-adrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje proteico sin Ig anti-ADM para reducir el riesgo de mortalidad en un paciente que padece una enfermedad crónica o aguda o un estado agudo
|
|
CN103308670B
(zh)
|
2012-03-08 |
2017-06-09 |
思芬构技术有限公司 |
用于预测对象患糖尿病和/或代谢综合征的风险的方法
|
|
CN103308673B
(zh)
|
2012-03-08 |
2017-05-31 |
思芬构技术有限公司 |
用于预测雌性对象中发生心血管事件的风险的方法
|
|
CN103308689B
(zh)
|
2012-03-08 |
2017-04-12 |
思芬构技术有限公司 |
用于预测雌性对象中患上癌症的风险或诊断癌症的方法
|
|
PT2846836T
(pt)
*
|
2012-05-07 |
2019-10-29 |
Allergan Inc |
Método de tratamento de dmi em doentes refratários à terapia anti-vegf
|
|
HUE055994T2
(hu)
|
2012-06-01 |
2022-01-28 |
Novartis Ag |
Fecskendõ
|
|
SG11201408196RA
(en)
*
|
2012-06-28 |
2015-03-30 |
Molecular Partners Ag |
Designed ankyrin repeat proteins binding to platelet-derived growth factor
|
|
AU2013100070B4
(en)
*
|
2012-07-03 |
2013-04-04 |
Novartis Ag |
Use of device
|
|
AU2012101678B4
(en)
|
2012-07-03 |
2013-01-24 |
Novartis Ag |
Use of device
|
|
DE202013000688U1
(de)
|
2012-07-03 |
2013-03-05 |
Novartis Ag |
Glas-Spritze
|
|
WO2014033184A1
(en)
*
|
2012-08-28 |
2014-03-06 |
Novartis Ag |
Use of a vegf antagonist in treating ocular vascular proliferative diseases
|
|
ES2810001T3
(es)
|
2012-10-02 |
2021-03-08 |
Sphingotec Gmbh |
Un método para diagnosticar o monitorizar la función renal
|
|
EP2738180A1
(en)
|
2012-11-30 |
2014-06-04 |
Molecular Partners AG |
Binding proteins comprising at least two binding domains against HER2.
|
|
RU2677895C2
(ru)
|
2013-01-08 |
2019-01-22 |
Сфинготек Гмбх |
Уровни гормона роста натощак в качестве прогностического маркера сердечно-сосудистого риска
|
|
WO2014131694A1
(en)
*
|
2013-02-26 |
2014-09-04 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
CN105188759A
(zh)
*
|
2013-03-14 |
2015-12-23 |
阿勒根公司 |
持续释放递送的组合物以及在制造过程中稳定蛋白质的方法
|
|
WO2014147153A1
(en)
|
2013-03-20 |
2014-09-25 |
Sphingotec Gmbh |
Adrenomedullin to guide therapy of blood pressure decline
|
|
FR3004650B1
(fr)
*
|
2013-04-22 |
2015-05-29 |
Affilogic |
Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation
|
|
US11453708B2
(en)
|
2013-05-31 |
2022-09-27 |
Molecular Partners Ag |
Designed ankyrin repeat proteins binding to hepatocyte growth factor
|
|
US20160129080A1
(en)
|
2013-06-20 |
2016-05-12 |
Aaron Osborne |
Treatment of polypoidal chroidal vasculopathy
|
|
US20160130321A1
(en)
|
2013-06-20 |
2016-05-12 |
Gabriela Burian |
Use of a vegf antagonist in treating macular edema
|
|
JP2016522249A
(ja)
|
2013-06-20 |
2016-07-28 |
ノバルティス アーゲー |
脈絡膜血管新生の治療におけるvegfアンタゴニストの使用
|
|
JP2016523956A
(ja)
|
2013-07-11 |
2016-08-12 |
ノバルティス アーゲー |
未熟児網膜症の治療におけるvegfアンタゴニストの使用
|
|
BR112016000177A2
(pt)
*
|
2013-07-11 |
2017-12-12 |
Novartis Ag |
usos de um antagonista do vegf no tratamento de doenças neovasculares coriorretinianas e de permeabilidade em pacientes pediátricos, seringa pré-cheia, kit e formulação de liberação lenta
|
|
SI4374873T1
(sl)
|
2013-07-12 |
2026-01-30 |
Astellas Us Llc |
Sredstvo za uporabo pri zdravljenju ali preprečevanju oftalmoloških stanj
|
|
EP3628324A1
(en)
*
|
2013-11-05 |
2020-04-01 |
Allergan, Inc. |
Method of treating conditions of the eye with an anti-vegf darpin
|
|
WO2015173260A1
(en)
|
2014-05-12 |
2015-11-19 |
Formycon Ag |
Pre-filled plastic syringe containing a vegf antagonist
|
|
EP3002589A1
(en)
|
2014-10-01 |
2016-04-06 |
sphingotec GmbH |
A method for stratifying a female subject for hormone replacement therapy
|
|
US9458211B1
(en)
*
|
2015-04-02 |
2016-10-04 |
Molecular Partners Ag |
Recombinant proteins that simultaneously bind HGF, VEGF-A and serum albumin, comprising ankyrin repeat domains
|
|
ES3075629T3
(en)
|
2015-04-24 |
2026-08-06 |
Sphingotec Gmbh |
A method for predicting the risk of incidence of chronic kidney disease
|
|
TWI799366B
(zh)
*
|
2015-09-15 |
2023-04-21 |
美商建南德克公司 |
胱胺酸結骨架平臺
|
|
KR102854749B1
(ko)
|
2015-11-18 |
2025-09-04 |
에스아이오2 메디컬 프로덕츠, 엘엘씨 |
안과 제제용 제약 패키지
|
|
US20180326126A1
(en)
|
2015-11-18 |
2018-11-15 |
Formycon Ag |
Pre-filled plastic syringe containing a vegf antagonist
|
|
CN108883172A
(zh)
|
2015-11-18 |
2018-11-23 |
福迈康股份公司 |
包含vegf拮抗剂的液体配制品的预填充药物包装
|
|
EP3407868A1
(en)
|
2016-01-26 |
2018-12-05 |
Formycon AG |
Liquid formulation of a vegf antagonist
|
|
WO2017148904A1
(en)
|
2016-02-29 |
2017-09-08 |
Franz Grus |
Predictive markers useful in the treatment of wet age-related macular degeneration
|
|
IL262472B2
(en)
|
2016-04-21 |
2024-12-01 |
4TEEN4 Pharmaceuticals GmbH |
Dpp3 inhibitors for use in treating diseases related to necrosis
|
|
US11390661B2
(en)
|
2016-06-27 |
2022-07-19 |
Aicuris Anti-Infective Cures Gmbh |
HCMV entry inhibitors
|
|
CN109716136B
(zh)
|
2016-07-08 |
2023-09-22 |
斯弗因高泰克有限公司 |
肾上腺髓质素用于评估急性心力衰竭患者的充血
|
|
SG10201912556VA
(en)
|
2016-07-20 |
2020-02-27 |
Aerpio Therapeutics Inc |
HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
|
|
MY196882A
(en)
|
2016-09-22 |
2023-05-08 |
Molecular Partners Ag |
Recombinant binding proteins and their use
|
|
EP3309550A1
(en)
|
2016-10-12 |
2018-04-18 |
sphingotec GmbH |
Method for the detection of apolipoprotein e4
|
|
EP3339324A1
(en)
|
2016-12-22 |
2018-06-27 |
sphingotec GmbH |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
|
|
KR20190120174A
(ko)
|
2016-12-16 |
2019-10-23 |
아드레노메드 아게 |
울혈의 중재 및 치료가 필요한 환자에서 울혈의 중재 및 치료에 사용하기 위한 항-아드레노메둘린 (ADM) 항체 또는 항-ADM 항체 단편 또는 항-ADM 비-Ig 스캐폴드
|
|
WO2018215580A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Method for sterilizing prefilled plastic syringes containing a vegf antagonist
|
|
US20200171244A1
(en)
|
2017-05-24 |
2020-06-04 |
Sio2 Medical Products, Inc. |
Sterilizable pharmaceutical package for ophthalmic formulations
|
|
WO2018217995A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
|
|
RU2019144031A
(ru)
|
2017-05-30 |
2021-06-30 |
Сфинготек Гмбх |
Способ диагностики или мониторинга функции почек или диагностики дисфункции почек
|
|
TW201904610A
(zh)
|
2017-06-14 |
2019-02-01 |
德商拜耳製藥公司 |
用於治療新生血管型青光眼之非抗體vegf拮抗劑
|
|
WO2019020777A1
(en)
|
2017-07-26 |
2019-01-31 |
Formycon Ag |
LIQUID FORMULATION OF A VEGF ANTAGONIST
|
|
CA3073125A1
(en)
*
|
2017-08-18 |
2019-02-21 |
Cambridge Enterprise Limited |
Modular binding proteins
|
|
US20220227854A1
(en)
|
2017-09-25 |
2022-07-21 |
Adrenomed Ag |
Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness
|
|
MX2020004072A
(es)
|
2017-10-18 |
2020-07-28 |
Adrenomed Ag |
Monitoreo de terapia bajo tratamiento con un aglutinante anti-adrenomodulina (adm).
|
|
RU2020115377A
(ru)
|
2017-10-24 |
2021-11-25 |
Сфинготек Гмбх |
Селенопротеин p для прогнозирования первого сердечно-сосудистого явления
|
|
KR102835427B1
(ko)
|
2017-10-25 |
2025-07-21 |
4틴4 파마슈티컬스 게엠베하 |
특이적 dpp3-에피토프에 대하여 지시되고 이에 결합하는 dpp3 결합제 및 산화적 스트레스와 연관되는 질환 / 급성 병태의 예방 또는 치료에서의 그의 용도
|
|
KR102717599B1
(ko)
|
2018-02-08 |
2024-10-14 |
스핑고텍 게엠베하 |
치매의 진단 및/또는 예측을 위한 아드레노메둘린 (adm) 및 치매의 요법 또는 예방에 사용하기 위한 항-아드레노메둘린 결합제
|
|
EP3569614A1
(en)
|
2018-05-18 |
2019-11-20 |
Julius-Maximilians-Universität Würzburg |
Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase
|
|
EP3586865A1
(en)
|
2018-06-21 |
2020-01-01 |
Charité - Universitätsmedizin Berlin |
Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis
|
|
EP3856245A4
(en)
|
2018-09-24 |
2022-10-26 |
EyePoint Pharmaceuticals, Inc. |
MULTISPECIFIC ANTIBODIES AGAINST HPTP - BETA (VE-PTP) AND VEGF
|
|
CA3124020A1
(en)
|
2018-12-20 |
2020-06-25 |
Sphingotec Gmbh |
Selenoprotein p in heart failure
|
|
US20220211798A1
(en)
|
2018-12-21 |
2022-07-07 |
4TEEN4 Pharmaceuticals GmbH |
Therapy guidance and/or therapy monitoring for a treatment with angiotensin-receptor-agonist and/or a precursor thereof
|
|
JP2022535564A
(ja)
|
2019-06-04 |
2022-08-09 |
モレキュラー パートナーズ アクチェンゲゼルシャフト |
多選択性タンパク質
|
|
US20220291234A1
(en)
|
2019-08-15 |
2022-09-15 |
Sphingotec Gmbh |
A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction in pediatric patients
|
|
WO2021038078A1
(en)
|
2019-08-30 |
2021-03-04 |
4TEEN4 Pharmaceuticals GmbH |
Therapy guidance and/or therapy monitoring for treatment of shock
|
|
AU2020402581A1
(en)
|
2019-12-11 |
2022-06-23 |
Molecular Partners Ag |
Designed ankyrin repeat domains with altered surface residues
|
|
EP3871689A1
(en)
|
2020-02-26 |
2021-09-01 |
sphingotec GmbH |
Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c
|
|
CN115244401A
(zh)
|
2020-02-27 |
2022-10-25 |
4Teen4制药有限公司 |
用于在休克患者中进行nt-adm抗体的治疗指导、监测和分层的dpp3
|
|
CN115244081A
(zh)
|
2020-02-27 |
2022-10-25 |
艾德里诺医药公司 |
用于治疗休克患者的抗肾上腺髓质素(adm)结合剂
|
|
CA3168978A1
(en)
|
2020-02-27 |
2021-09-02 |
Andreas Bergmann |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
|
|
US20210285949A1
(en)
|
2020-03-16 |
2021-09-16 |
Sphingotec Gmbh |
Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin
|
|
US20230213519A1
(en)
|
2020-03-16 |
2023-07-06 |
4TEEN4 Pharmaceuticals GmbH |
Dpp3 in patients infected with coronavirus
|
|
EP3922993A1
(en)
|
2020-06-12 |
2021-12-15 |
4TEEN4 Pharmaceuticals GmbH |
Dpp3 in patients infected with coronavirus
|
|
MX2022013945A
(es)
|
2020-05-06 |
2023-02-14 |
Molecular Partners Ag |
Nuevas proteinas de union a repeticiones de anquirina y sus usos.
|
|
IL298168A
(en)
|
2020-05-14 |
2023-01-01 |
Molecular Partners Ag |
Multispecific proteins
|
|
EP4023218A1
(en)
|
2020-12-02 |
2022-07-06 |
S-Form Pharma |
Combination therapy for patients having acute and/or persistent dyspnea
|
|
AU2021403658A1
(en)
*
|
2020-12-16 |
2023-06-29 |
Molecular Partners Ag |
Recombinant cd3 binding proteins and their use
|
|
US20240108746A1
(en)
|
2020-12-16 |
2024-04-04 |
Molecular Partners Ag |
Novel slow-release prodrugs
|
|
US20240317852A1
(en)
|
2021-03-09 |
2024-09-26 |
Molecular Partners Ag |
Novel darpin based cd33 engagers
|
|
EP4305063A1
(en)
|
2021-03-09 |
2024-01-17 |
Molecular Partners AG |
Protease cleavable prodrugs
|
|
WO2022190016A1
(en)
|
2021-03-09 |
2022-09-15 |
Molecular Partners Ag |
Novel darpin based multi-specific t-cell engagers
|
|
CA3211368A1
(en)
|
2021-03-09 |
2022-09-15 |
Molecular Partners Ag |
Novel darpin based cd123 engagers
|
|
EP4329734A4
(en)
|
2021-04-26 |
2025-04-02 |
Celanese EVA Performance Polymers LLC |
Implantable device for the delayed release of a macromolecular drug compound
|
|
US20240272178A1
(en)
|
2021-06-18 |
2024-08-15 |
Sphingotec Gmbh |
A method for predicting sepsis and septic shock
|
|
WO2023275099A1
(en)
|
2021-06-29 |
2023-01-05 |
Berysol Gmbh |
Composite biomarker for the identification of selenium deficiency in a bodily fluid
|
|
EP4145456A1
(en)
|
2021-09-06 |
2023-03-08 |
Bayer AG |
Prediction of a change related to a macular fluid
|
|
WO2023110983A1
(en)
|
2021-12-14 |
2023-06-22 |
Molecular Partners Ag |
Designed repeat domains with dual binding specificity and their use
|
|
CN119072492A
(zh)
|
2022-03-15 |
2024-12-03 |
艾德里诺医药公司 |
抗肾上腺髓质素(adm)抗体或抗adm抗体片段的稳定水性制剂
|
|
IL318667A
(en)
|
2022-07-29 |
2025-03-01 |
Adrenomed Ag |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
|
|
US20260028423A1
(en)
|
2022-07-29 |
2026-01-29 |
4TEEN4 Pharmaceuticals GmbH |
Prediction of an increase of dpp3 in a patient with septic shock
|
|
CA3262553A1
(en)
|
2022-08-01 |
2024-02-08 |
Molecular Partners Ag |
REHEARSAL AREAS DESIGNED WITH MODIFIED CHARGES AND THEIR USE
|
|
WO2024038307A1
(en)
|
2022-08-19 |
2024-02-22 |
Novartis Ag |
Dosing regimens for sars-cov-2 binding molecules
|
|
WO2024059686A2
(en)
*
|
2022-09-15 |
2024-03-21 |
The Regents Of The University Of California |
Darpin backbones and rigidified electron microscopy imaging scaffolds
|
|
US20260201067A1
(en)
|
2022-12-15 |
2026-07-16 |
4TEEN4 Pharmaceuticals GmbH |
Dpp3 inhibitor for improvement of pulmonary function in critically ill patients
|
|
EP4673159A1
(en)
|
2023-02-27 |
2026-01-07 |
Molecular Partners AG |
Darpins for use in reducing renal accumulation of drugs
|
|
EP4680966A1
(en)
|
2023-03-17 |
2026-01-21 |
PAM Theragnostics GmbH |
Methods for determining peptidylglycine alpha-amidating monooxygenase (pam) and its use for diagnostic purpose
|
|
JP2026513177A
(ja)
|
2023-03-29 |
2026-04-23 |
4ティーン4 ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング |
血圧低下を有する重症患者における心筋保護及び心筋傷害の予防のためのdpp3阻害剤
|
|
CN121889677A
(zh)
|
2023-09-25 |
2026-04-17 |
思芬构技术有限公司 |
用于肾移植患者中移植物功能降低的早期诊断、早期预测、监测或严重程度预测的方法
|
|
WO2025146491A1
(en)
|
2024-01-05 |
2025-07-10 |
Molecular Partners Ag |
Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent
|
|
WO2025229075A1
(en)
|
2024-05-03 |
2025-11-06 |
Sphingotec Gmbh |
A method for the specific determination of proenkephalin fragment 119-159
|
|
WO2025248139A1
(en)
|
2024-05-31 |
2025-12-04 |
4TEEN4 Pharmaceuticals GmbH |
Use of adrenomedullin or fragments thereof in the treatment of a patient in need thereof
|
|
EP4675277A1
(en)
|
2024-07-05 |
2026-01-07 |
Predemtec AG |
A method for diagnosing alzheimer´s disease or determining the risk of suffering from alzheimer´s disease
|
|
WO2026046978A1
(en)
|
2024-08-26 |
2026-03-05 |
Pam Theragnostics Gmbh |
Anti-adm antibodies, anti-adm antibody fragment or anti-adm non-ig scaffold for therapy or prevention of immune effector cell therapy side effects
|
|
WO2026046968A1
(en)
|
2024-08-26 |
2026-03-05 |
4TEEN4 Pharmaceuticals GmbH |
Dpp3 binders for the treatment of endothelial dysfunction
|